SequelSEC

RECURSION PHARMACEUTICALS, INC. RXRX

Biological Products, (No Diagnostic Substances) · CIK 0001601830 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$54.86M
Fiscal year ended 2026-06-30
Operating income
-$544.01M
Fiscal year ended 2026-06-30
Free cash flow
-$352.27M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$2.03BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue27.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity0.01x12th
Gross margin5.0%12th
SBC / revenue148.9%74th
CapEx / revenue8.7%68th
Revenue YoY growth26.9%64th
FCF margin-506.5%39th
Net margin-863.4%39th
Operating margin-867.9%40th
R&D / revenue636.4%57th
Current ratio5.50x56th

RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $54.86M and net income of -$518.88M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from RECURSION PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

RECURSION PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$54.86M
Cost of revenue$52.94M
Gross profit$1.91M
Operating income-$544.01M
Net income-$518.88M
Research & development$394.51M
Weighted-average diluted sharesUnavailable
Pretax income-$523.47M
Income tax expense-$4.58M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$151.41M
Selling & marketingUnavailable

Balance

RECURSION PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$545.68M
Total assets$1.21B
Current assets$603.46M
Total liabilities$297.66M
Current liabilities$119.89M
Total equity incl. NCI$915.00M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$160.35M
Long-term debt$4.75M
Accounts payable$12.67M

Cash flow

RECURSION PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$350.48M
Capital expenditures$1.79M
Investing cash flow-$6.09M
Financing cash flow$378.61M
Net change in cash$22.98M
Stock-based compensation$90.72M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$78.36M

Derived

RECURSION PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$352.27M
Gross margin3.5%
Operating margin-991.7%
FCF margin-642.2%
SBC / revenue165.4%
Current ratio5.03x
Revenue YoY growth-15.1%
Net margin-945.9%
R&D / revenue719.2%
CapEx / revenue3.3%
Long-term debt / equity0.01x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RXRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.